Vaxart Inc

Vaxart Inc(VXRT)股票分析

$0.320

-0.080 (-25.06%)收盤時

Loading chart…
最高
0.430
開盤
0.412
成交量加權均價
0.35
成交量
24.02M
市值
118.17M
最低
0.300
成交金額
8.41M
企業價值/稅息折舊攤銷前利潤(TTM)
-7.36

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.

估值指標

Vaxart Inc(VXRT)目前預期本益比為 -1.49,5 年平均預期本益比為 -2.67。

預期本益比

合理
5 年均值 P/E
-2.67
目前P/E
-1.49
高估
-0.51
低估
-4.83

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-3.94
目前EV/EBITDA
-7.36
高估
5.18
低估
-13.06

預期股價營收比

合理
5 年均值 P/S
185.47
目前P/S
3.41
高估
616.15
低估
-245.22

Alphio AI 對 VXRT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%VXRT

$1.66

情境價格

基

基準

基準 · 50%VXRT

$1.28

情境價格

悲

悲觀

悲觀 · 25%VXRT

$0.91

情境價格

事件時間軸

2026-07-06 (ET)

16:30:00

Vaxart Announces Safety Data from COVID-19 Oral Vaccine Trial

2026-07-01 (ET)

16:30:00

Vaxart Resolves Proxy Contest, Seeks Independent Director

2026-06-25 (ET)

09:30:00

Vaxart Secures $29M Funding for Oral Vaccine Trial

2026-01-15 (ET)

08:20:00

Vaxart Publishes Phase 1 Trial Data Showing Vaccine Efficacy in Breastfeeding Women

2025-11-05 (ET)

16:03:09

Dynavax Secures Licensing Deal for Vaxart's Oral COVID-19 Vaccine Initiative

資訊

VXRT 常見問題 —— 由 Alphio AI 解答

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易